<?xml version="1.0" encoding="UTF-8"?><safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-44</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150313</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150304</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150304</receiptdate>
		<additionaldocument>2</additionaldocument>
		<documentlist/>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb/>
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-44</companynumb>
		<duplicate>1</duplicate>
		<casenullification/>
		<nullificationreason/>
		<medicallyconfirm/>
		<reportduplicate>
			<duplicatesource/>
			<duplicatenumb>201504950</duplicatenumb>
		</reportduplicate>
		<primarysource>
			<reportertitle>DR</reportertitle>
			<reportergivename>Masaru</reportergivename>
			<reportermiddlename/>
			<reporterfamilyname>Takemura</reporterfamilyname>
			<reporterorganization>Dokkyo Medical University</reporterorganization>
			<reporterdepartment/>
			<reporterstreet/>
			<reportercity/>
			<reporterstate>Tochigi</reporterstate>
			<reporterpostcode/>
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<literaturereference>Takemura M. Experience of Two Cases Presenting with Withdrawal Signs Due to Interruption of Oral Treatment with Weak Opioid. 44th Annual Meeting of the Japanese Society for the Study of Chronic Pain - Abstract of Congress. 2015;101:3</literaturereference>
			<studyname/>
			<sponsorstudynumb/>
			<observestudytype/>
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename/>
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate/>
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype/>
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment/>
			<receivertitle/>
			<receivergivename/>
			<receivermiddlename/>
			<receiverfamilyname/>
			<receiverstreetaddress/>
			<receivercity/>
			<receiverstate/>
			<receiverpostcode/>
			<receivercountrycode/>
			<receivertel/>
			<receivertelextension/>
			<receivertelcountrycode/>
			<receiverfax/>
			<receiverfaxextension/>
			<receiverfaxcountrycode/>
			<receiveremailaddress/>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientgpmedicalrecordnumb/>
			<patientspecialistrecordnumb/>
			<patienthospitalrecordnumb/>
			<patientinvestigationnumb/>
			<patientbirthdateformat/>
			<patientbirthdate/>
			<patientonsetage>44</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod/>
			<gestationperiodunit/>
			<patientagegroup/>
			<patientweight/>
			<patientheight/>
			<patientsex>2</patientsex>
			<lastmenstrualdateformat/>
			<patientlastmenstrualdate/>
			<patientmedicalhistorytext>The patient's history of drug abuse/illicit drug use, alcohol use and smoking was not reported</patientmedicalhistorytext>
			<resultstestsprocedures/>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10033371</patientepisodename>
				<patientmedicalstartdateformat/>
				<patientmedicalstartdate/>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat/>
				<patientmedicalenddate/>
				<patientmedicalcomment/>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10029173</patientepisodename>
				<patientmedicalstartdateformat/>
				<patientmedicalstartdate/>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat/>
				<patientmedicalenddate/>
				<patientmedicalcomment>stellate ganglion block</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10041554</patientepisodename>
				<patientmedicalstartdateformat/>
				<patientmedicalstartdate/>
				<patientmedicalcontinue/>
				<patientmedicalenddateformat/>
				<patientmedicalenddate/>
				<patientmedicalcomment>cervical cord injury</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10039203</patientepisodename>
				<patientmedicalstartdateformat/>
				<patientmedicalstartdate/>
				<patientmedicalcontinue/>
				<patientmedicalenddateformat/>
				<patientmedicalenddate/>
				<patientmedicalcomment>approximately 10 years before</patientmedicalcomment>
			</medicalhistoryepisode>
			<patientpastdrugtherapy>
				<patientdrugname>BUPRENORPHINE HYDROCHLORIDE</patientdrugname>
				<patientdrugstartdateformat/>
				<patientdrugstartdate/>
				<patientdrugenddateformat/>
				<patientdrugenddate/>
				<patientindicationmeddraversion/>
				<patientdrugindication/>
				<patientdrgreactionmeddraversion>17.1</patientdrgreactionmeddraversion>
				<patientdrugreaction>10048768</patientdrugreaction>
			</patientpastdrugtherapy>
			<reaction>
				<primarysourcereaction>WITHDRAWAL REACTION</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10048008</reactionmeddrallt>
				<reactionmeddraversionpt/>
				<reactionmeddrapt/>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat/>
				<reactionstartdate/>
				<reactionenddateformat/>
				<reactionenddate/>
				<reactionduration/>
				<reactiondurationunit/>
				<reactionfirsttime/>
				<reactionfirsttimeunit/>
				<reactionlasttime/>
				<reactionlasttimeunit/>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>THERAPY INTERRUPTED</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10064294</reactionmeddrallt>
				<reactionmeddraversionpt/>
				<reactionmeddrapt/>
				<termhighlighted>1</termhighlighted>
				<reactionstartdateformat/>
				<reactionstartdate/>
				<reactionenddateformat/>
				<reactionenddate/>
				<reactionduration/>
				<reactiondurationunit/>
				<reactionfirsttime/>
				<reactionfirsttimeunit/>
				<reactionlasttime/>
				<reactionlasttimeunit/>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>TRAMCET</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb>GB Mkt</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>Non-Gruenenthal</drugauthorizationholder>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit>32</drugstructuredosageunit>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext>2 DF, 3/day</drugdosagetext>
				<drugdosageform>Film-coated tablet</drugdosageform>
				<drugadministrationroute>48</drugadministrationroute>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>6</actiondrug>
				<drugrecurreadministration>2</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10064294</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Not applicable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10064294</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>TRAMCET</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb>GB Mkt</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>Non-Gruenenthal</drugauthorizationholder>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit>32</drugstructuredosageunit>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext>2 DF, 3/day</drugdosagetext>
				<drugdosageform>Film-coated tablet</drugdosageform>
				<drugadministrationroute/>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion/>
				<drugindication/>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>6</actiondrug>
				<drugrecurreadministration>2</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10048008</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10064294</drugreactionasses>
					<drugassessmentsource>GRUNENTHAL</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Not applicable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10064294</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>GLOBAL INTROSPECTION</drugassessmentmethod>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Manufacturer Control Number: 2015-11648This spontaneous literature case from Japan was reported by a physician via license partner and was initially received on 04-Mar-2015. It concerns a 44-year-old female patient (height and weight unknown).The patient's medical history and concurrent conditions included pain, nerve block, spinal cord injury cervical, road traffic accident and dermatosis under previous buprenorphine hydrochloride treatment.The patient was treated with tramadol hydrochloride, paracetamol (Tramcet, film-coated tablet, oral) 2 df 3/day initiated on an unspecified date for pain.No other suspected medication was reported.No relevant concomitant medication was reported.On an unspecified date, the patient experienced withdrawal syndrome.Although the patient had been receiving treatment with stellate ganglion block for cervical cord injury after traffic injury experienced approximately 10 years before, no effective alleviation of pain had been achieved, for which prescription of opioid analgesics was started. Although buprenorphine hydrochloride patch was used to avoid high-dose oral treatment, severe cutaneous symptoms (dermatosis) developed, for which the opioid treatment was switched to tramadol/apap, initiated on an unspecified date.On an unspecified date thereafter, the pain was alleviated, and the symptoms were stabilized for approximately 3 months, but the treatment with tramadol/apap was interrupted (drug dose omission) at the patient's discretion on the day of her child's athletic meeting for fear of onset of sleepiness during the athletic meeting and as a result, she experienced withdrawal symptoms such as cold sweat and restlessness. The oral treatment with tramadol/apap was resumed after the athletic meeting had been completed, and the symptoms disappeared.No relevant laboratory data were reported.No treatment of the AEs was reported.The outcome of withdrawal syndrome was reported as recovered/resolved.No further information was available.Literature citation:takemura m. experience of two cases presenting with withdrawal signs due to interruption of oral treatment with weak opioid. 44th annual meeting of the japanese society for the study of chronic pain; feb-2015. abstract of congress. 2015;101***Third party case numbers:e2b company number: jp-jnjfoc-20150306405e2b report duplicate: 201504950</narrativeincludeclinical>
				<reportercomment/>
				<senderdiagnosismeddraversion/>
				<senderdiagnosis/>
				<sendercomment>Withdrawal syndrome is assessed as serious.Withdrawal syndrome is listed in the Company Core Data Sheet of tramadol hydrochloride, paracetamol (oral).Withdrawal syndrome is assessed to be possibly related to the administration of tramadol hydrochloride, paracetamol.Drug dose omission is not considered to be an adverse reaction, as only its possible consequences would be reactions. Therefore, seriousness, listedness, and causality are assessed to be not applicable.The information in this single case does not appear to alter the favorable benefit to risk ratio of tramadol hydrochloride, paracetamol.Time to onset is plausible, and withdrawal symptoms belong to the known reaction pattern for tramadol hydrochloride, paracetamol. Hence, withdrawal reaction is assessed to be possibly related to the administration of tramadol hydrochloride, paracetamol.The additionally reported events of cold sweat and restlessness were deleted, as they are considered to be symptoms of the diagnosed withdrawal syndrome.</sendercomment>
			</summary>
		</patient>
	</safetyreport>